GW590735

• CAT Number: I007151
• CAS Number: 622402-22-6
• Molecular Formula: C23H21F3N2O4S
• Molecular Weight: 478.486
• Purity: ≥95%
• Target: PPAR
• Solubility: Soluble in DMSO, not in water
• Storage: Store at -20°C
• IUPAC Name: 2-methyl-2-[4-[[[4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazole-5-carbonyl]amino]methyl]phenoxy]propanoic acid
• InChI: InChI=1S/C23H21F3N2O4S/c1-13-18(33-20(28-13)15-6-8-16(9-7-15)23(24,25)26)19(29)27-12-14-4-10-17(11-5-14)32-22(2,3)21(30)31/h4-11H,12H2,1-3H3,(H,27,29)(H,30,31)
• InChIKey: ILUPZUOBHCUBKB-UHFFFAOYSA-N
• SMILES: CC1=C(SC(=N1)C2=CC=C(C=C2)C(F)(F)F)C(=O)NCC3=CC=C(C=C3)OC(C)(C)C(=O)O

GW590735 (Cat.No:I007151) is a potent and selective agonist of PPARα with an EC50 value of 4 nM for the expression a GAL4-responsive reporter gene and at least 500-fold selectivity versus PPARγ and PPARδ. GW590735 significantly increased HDL cholesterol, decreased LDL and VLDL cholesterol, and significantly reduced triglycerides. Maximal increases in HDL cholesterol were 37%, 53%, and 84% with fenofibrate, torcetrapib, and GW590735, respectively.

Reference

1:Hansen MK, McVey MJ, White RF, Legos JJ, Brusq JM, Grillot DA, Issandou M, Barone FC. Selective CETP inhibition and PPARalpha agonism increase HDL cholesterol and reduce LDL cholesterol in human ApoB100/human CETP transgenic mice. J Cardiovasc Pharmacol Ther. 2010 Jun;15(2):196-202. doi: 10.1177/1074248410362891. Epub 2010 Mar 23. PubMed PMID: 20332533.